Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Cherenkov Effect Breakthrough Allows Clinicians to Visualize Radiotherapy in Body

By BiotechDaily International staff writers
Posted on 05 Feb 2014
Image: Long exposure image of Cherenkov emission and induced fluorescence from fluorescein dissolving in water during irradiation from a therapeutic LINAC (linear particle accelerator) beam (Photo courtesy of Dartmouth engineering PhD candidate Adam Glaser).
Image: Long exposure image of Cherenkov emission and induced fluorescence from fluorescein dissolving in water during irradiation from a therapeutic LINAC (linear particle accelerator) beam (Photo courtesy of Dartmouth engineering PhD candidate Adam Glaser).
Image: A radiation beam treatment is visualized here in the first in human use of the technique. The blue represents the treatment area. As the dose fades, the treatment area becomes a dark gray shadow (Photo courtesy of Dartmouth University).
Image: A radiation beam treatment is visualized here in the first in human use of the technique. The blue represents the treatment area. As the dose fades, the treatment area becomes a dark gray shadow (Photo courtesy of Dartmouth University).
A scientific breakthrough may provide radiation oncologists with new tools to increase the accuracy and safety of radiation treatment in cancer patients by helping them visualize the powerful beams of a linear accelerator as they enter or exit the body.

Dartmouth University (Hanover, NH, USA) began to study a scientific phenomenon called the Cherenkov Effect in 2011. The scientists and engineers hypothesized that by using Cherenkov emissions the beam of radiation could be “visible” to the treatment team. The capability to seize a beam of radiation would show: how the radiation signals move through the body, the dose of radiation to the skin, and any errors in dosage.

Scientists, for the first time in humans, have used the technology, and the first case was a female breast cancer patient undergoing radiation. “Breast cancer is suited for this because the imaging visualizes the superficial dose of radiation to the skin,” said Lesley A. Jarvis, MD, radiation oncologist, Norris Cotton Cancer Center. Similar to sunburn, skin reactions are a typical and annoying side effect during breast radiation. “By imaging and quantitating the surface dose in a way that has never been done before,” said Dr. Jarvis, “we hope to learn more about the physical factors contributing to this skin reaction.”

By seeing the effect of radiation on the body, Dartmouth’s Norris Cotton Cancer Center radiation oncologists and physicists can make adjustments to avoid side effects to the skin. Most radiation patients undergo somewhere between 8–20 sessions. The Cherenkov images of the breast cancer patient showed a hot spot in her underarm, which physicians and physicists could work to prevent in future sessions. “The actual images show that we are treating the exact correct location, with the appropriate beam modifications and with the precise dose of radiation,” stated Dr. Jarvis.

This trial revealed that the Cherenkov Effect is feasible for use real-time during radiation. “We have learned the imaging is easy to incorporate into the patient's treatment, adding only minimal time to the treatments,” said Dr. Jarvis.

This was the first time Cherenkov studies came out of the laboratory and into a treatment setting. The scientists coined the approach Cherenkoscopy. As they anticipated, during the session they were able to see comprehensive data about the treatment field and the dose. The findings were published in the November 2013 issue of the Journal of Biomedical Optics. “This first observation in the dog proved that we could image a radiation beam during treatment in real time,” said David Gladstone, ScD, chief of clinical physics at Norris Cotton Cancer Center. “The images verified the shape of the beam as well as intended motion of the treatment machine. The time needed to acquire this information is negligible, even with our experimental, nonintegrated system.”

By incorporating Cherenkov imaging technology into routine clinical care, Dr. Gladstone reported that the technology could be used to prove that the correct dose is being delivered to patients, helping to avoid misadministration of radiation therapy, a rare, but dangerous occurrence. “The time needed to acquire this information is negligible, even with our experimental, nonintegrated system,” said Dr. Gladstone. “Cherenkov images were found to contain much richer information than anticipated, specifically, we did not expect to visualize internal blood vessels.”

Twelve patients are participating in a pilot study, which is almost complete. The researchers now plan to publish their findings.

Related Links:

Dartmouth University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.